A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration | NCT00346957 | Trialant
CompletedInterventionalPhase 2Updated Mar 6, 2012
A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration
ClinicalTrials.gov ID
NCT00346957
Lead Sponsor
Alcon ResearchINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
128Actual
Last Update Posted
Mar 6, 2012Estimated
Start Date
Apr 1999
Primary Completion Date
Apr 2003Actual
Completion Date
Apr 2003Actual
Brief Summary
The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.
AMD
Anecortave acetate 30 mg
Anecortave Acetate 15 mg
Anecortave Acetate 3 mg
Anecortave Acetate Vehicle
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Ages 50 years and over
Other protocol-defined inclusion and exclusion criteria may apply.